UCB SA, founded in 1928 and headquartered in Brussels, Belgium, is a global biopharmaceutical company focused on the discovery and development of innovative medicines for severe diseases, particularly in neurology and immunology. The company specializes in therapies for conditions such as epilepsy, multiple sclerosis, and Crohn's disease, positioning itself as a key player in the pharmaceutical industry.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| UCBBB 1.00% 2027-10-01 EURUCB SA | Belgium | 2027-10-01 | 1.000 | 3.51 |
| UCBBB 1.00% 2028-03-30 EURUCB SA | Belgium | 2028-03-30 | 1.000 | 2.97 |
| UCBBB 4.25% 2030-03-20 EURUCB SA | Belgium | 2030-03-20 | 4.250 | 3.35 |
| UCBBB 5.20% 2029-11-21 EURUCB SA | Belgium | 2029-11-21 | 5.200 | 3.47 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
UCB SA began issuing bonds in 2005, with notable issuances including a €500 million bond to refinance existing debt and support its research initiatives. In recent years, UCB has maintained attractive yields for investors, typically lower than the industry average, reflecting its solid credit standing and stable cash flows. The company recently announced the launch of a new green bond framework, aiming to enhance its sustainability efforts and attract socially responsible investors, a move that aligns with growing market trends favoring environmental considerations in corporate financing.